Search research articles
Contact Us
Filters
Showing results (161-170 of 201) with videos related to
Page
of 21
Sort By:
Cancer Chemotherapy and Pharmacology
|
July 18, 2018
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
Amita Patnaik, Michael Gordon, Frank Tsai, et al.
Cancer Chemotherapy and Pharmacology
|
June 22, 2018
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
Amita Patnaik, Michael Gordon, Frank Tsai, et al.
Gynecologic Oncology
|
June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
Joyce F Liu, Michael Gordon, Jennifer Veneris, et al.
Journal of Nanobiotechnology
|
November 19, 2024
Physical, biochemical, and biological characterization of olive-derived lipid nanovesicles for drug delivery applications
Zhu Zhao, Jerome Lacombe, Laurianne Simon, et al.
Nature Communications
|
August 13, 2021
Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Antoni Ribas, Alain Algazi, Paolo A Ascierto, et al.
JAMA Oncology
|
August 18, 2022
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG)
Roberta Sanfilippo, Richard L Hayward, Jammbe Musoro, et al.
Nature Communications
|
December 8, 2020
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Antoni Ribas, Alain Algazi, Paolo A Ascierto, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 11, 2004
Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring
Donald M McDonald, Beverly A Teicher, William Stetler-Stevenson, et al.
Contemporary Clinical Trials
|
January 21, 2015
Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial
Joshua D Lee, Peter D Friedmann, Tamara Y Boney, et al.
Health & Justice
|
October 14, 2014
A cluster randomized trial of an organizational linkage intervention for offenders with substance use disorders: study protocol
Peter D Friedmann, Lori J Ducharme, Wayne Welsh, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 201) with videos related to
Sort By:
Page
of 21
Cancer Chemotherapy and Pharmacology
|
July 18, 2018
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
Amita Patnaik, Michael Gordon, Frank Tsai, et al.
Cancer Chemotherapy and Pharmacology
|
June 22, 2018
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
Amita Patnaik, Michael Gordon, Frank Tsai, et al.
Gynecologic Oncology
|
June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
Joyce F Liu, Michael Gordon, Jennifer Veneris, et al.
Journal of Nanobiotechnology
|
November 19, 2024
Physical, biochemical, and biological characterization of olive-derived lipid nanovesicles for drug delivery applications
Zhu Zhao, Jerome Lacombe, Laurianne Simon, et al.
Nature Communications
|
August 13, 2021
Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Antoni Ribas, Alain Algazi, Paolo A Ascierto, et al.
JAMA Oncology
|
August 18, 2022
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG)
Roberta Sanfilippo, Richard L Hayward, Jammbe Musoro, et al.
Nature Communications
|
December 8, 2020
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Antoni Ribas, Alain Algazi, Paolo A Ascierto, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 11, 2004
Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring
Donald M McDonald, Beverly A Teicher, William Stetler-Stevenson, et al.
Contemporary Clinical Trials
|
January 21, 2015
Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial
Joshua D Lee, Peter D Friedmann, Tamara Y Boney, et al.
Health & Justice
|
October 14, 2014
A cluster randomized trial of an organizational linkage intervention for offenders with substance use disorders: study protocol
Peter D Friedmann, Lori J Ducharme, Wayne Welsh, et al.
Page
of 21